Deirdre K and Catherine MK
Thyroid cancer represents a spectrum of biological and molecular activity. As such it can behave in a variety of ways. This makes metastatic thyroid cancer challenging to manage. In advanced rapidly progressive thyroid cancer new agents and multimodality care represent promising therapeutic options for patients. However, these agents are not without risk and clinicians must be judicious with their use, weighing toxicities, quality of life and likely benefits. We review the presentation, treatment and prognosis of thyroid cancer subtypes as well as the recent developments in targeted therapy for medullary thyroid cancer. We discuss the role of cytotoxic therapy in thyroid cancer and review recent trials of novel agents and currently recruiting trials.
Partagez cet article
English 
Spanish 
Chinese 
Russian 
German 
Japanese 
Portuguese 
Hindi 